Glioma

Orphan designation: Autologous CD34+ haematopoietic stem and progenitor cells transduced with a lentiviral vector encoding the interferon alpha-2 gene Treatment of glioma, 20/06/2023 Positive

Retrieved on: 
Sunday, February 4, 2024
COMP, IRIS, EMA, European Commission, Patient, Science, Autotransplantation, Committee, Glioma, Pharmaceutical industry

Key facts

Key Points: 
  • Key facts
    - Active substance
    - Autologous CD34+ haematopoietic stem and progenitor cells transduced with a lentiviral vector encoding the interferon alpha-2 gene
    - Intended use
    - Treatment of glioma
    - Orphan designation status
    - Positive
    - EU designation number
    - EU/3/23/2794
    - Date of designation
    - Sponsor
    Genenta Science S.p.A.
  • Patients' organisations
    For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
    European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • EU register of orphan medicines
    The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:
    EMA list of opinions on orphan medicinal product designation
    EMA publishes information on orphan medicinal product designation adopted by the Committee for Orphan Medicinal Products (COMP) on the IRIS online platform:

FRED’S TEAM SETS HISTORIC $8 MILLION FUNDRAISING RECORD FOR CANCER RESEARCH

Retrieved on: 
Wednesday, January 17, 2024
IDH, Brain, Patient, Glioma, Research, Berlin Marathon, MD, New York City Marathon, Life, Neuro, TCS, MSK, Neuro-Oncology (journal), Cancer, Nursing, Division, Running, Neurology, Pharmaceutical industry

New York, NY, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Fred’s Team, the official running program of Memorial Sloan Kettering Cancer Center (MSK), set a new single-season fundraising record in 2023 by raising $8 million for cancer research at MSK.

Key Points: 
  • New York, NY, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Fred’s Team, the official running program of Memorial Sloan Kettering Cancer Center (MSK), set a new single-season fundraising record in 2023 by raising $8 million for cancer research at MSK.
  • This new milestone is a testament to the Fred’s Team community’s enduring commitment to MSK’s mission of ending cancer for life.
  • Since 1995, Fred’s Team donors and participants have directed more than $112 million to MSK.
  • Fred’s Team participants get to choose the area of cancer research at MSK that they support with their miles.

Lisata Therapeutics Announces First Patient Treated in the Phase 2a Trial of LSTA1 in Patients with Glioblastoma Multiforme

Retrieved on: 
Wednesday, January 17, 2024
Patient, Permeability, Therapy, Glioblastoma, SOC, Standard of care, Tartu University Clinic, GBM, Traffic barrier, Doctor of Philosophy, Temozolomide, Glioma

The trial is an investigator-initiated study by Lenne-Triin Kõrgvee, MD, PhD, principal investigator of the study.

Key Points: 
  • The trial is an investigator-initiated study by Lenne-Triin Kõrgvee, MD, PhD, principal investigator of the study.
  • The study is a Phase 2a, double-blind, placebo-controlled, randomized, proof-of-concept study evaluating LSTA1 when added to standard of care (“SoC”), temozolomide, versus SoC and placebo in subjects with newly diagnosed GBM.
  • “We are very pleased to announce the first patient treated in this Phase 2a study evaluating LSTA1 in patients with newly diagnosed GBM, a very aggressive brain tumor that is often fatal.
  • “GBM has, historically, been very difficult to successfully treat and we believe LSTA1 may be an important tool in improving those outcomes for patients.”

ChromaCode Announces Publication of New Study Demonstrating the Superior Performance of its HDPCR NSCLC Assay Compared to NGS with Low Sample Input

Retrieved on: 
Friday, January 26, 2024
NGS, National Comprehensive Cancer Network, Patient, Glioma, DNA, RNA, PPA, Diagnosis, Cholangiocarcinoma, Genomics, NCCN, Lung cancer, Guideline, Thyroid, Medical imaging

ChromaCode's HDPCR technology helps to address low sample input, which is a common issue with core biopsy specimens used in the diagnosis of non-small cell lung cancer (NSCLC) and other tumor types.

Key Points: 
  • ChromaCode's HDPCR technology helps to address low sample input, which is a common issue with core biopsy specimens used in the diagnosis of non-small cell lung cancer (NSCLC) and other tumor types.
  • The HDPCR NSCLC Panel is an ideal test for National Comprehensive Cancer Network (NCCN) guideline directed clinically relevant variants.
  • "We have leveraged our HDPCR technology to build a rapid and cost-effective first line assay in NSCLC, covering 99.6% of prevalent NCCN variants.
  • The findings suggest that HDPCR emerges as a precise and efficient approach for identifying clinically relevant NSCLC mutations, even with low nucleotide input and quality.

Oncotelic Therapeutics Announces Clinical Linkage of TGFB2 and IFNGR2 in Pediatric DMG Patients

Retrieved on: 
Tuesday, January 16, 2024
Mortality, Neoplasm, Patient, CD163, JAK1, Therapy, Research, Survival, Cancer, CD86, TGF-B2, OTCQB, STAT1, APC, HR, CD14, TGFB2, Interferon gamma, Messenger, TME, DMG, Glioma, Vaccine

We hope that sharing these findings from our research team will contribute to the eradication of cancer," stated Dr. Vuong Trieu, CEO and Chairman of Oncotelic.

Key Points: 
  • We hope that sharing these findings from our research team will contribute to the eradication of cancer," stated Dr. Vuong Trieu, CEO and Chairman of Oncotelic.
  • IFNGR2 is a critical component of the IFN-γ signaling pathway, playing a significant role in mediating the immune system's defense against cancer.
  • The expression levels of IFNGR2 and TGFB2 (1.51-fold increase (p = 0.002) and 1.58-fold increase (p = 5.5 × 10−4), respectively) were significantly upregulated in pbDMG tumors compared with normal brainstem/pons samples.
  • Worse survival outcomes in pbDMG patients when comparing high versus low TGFB2 levels in the context of low IFNGR2 levels suggest that the abrogation of the TGFB2 mRNA expression in the immunologically cold tumor microenvironment can be used to treat pbDMG patients.

Janux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific Officer

Retrieved on: 
Monday, January 8, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Neck, CD28, GSK plc, B.S.E, Glioma, PSMA, Acquisition, Lung, Colorectal cancer, Breast, EGFR, Renal cell carcinoma, Chemical engineering, Therapy, Stanford University, Head, University, Prostate, IP, Pharmaceutical engineering, CSO, PD-L1, Pharmaceutical industry

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the promotion of Dr. Tommy DiRaimondo to Chief Scientific Officer.

Key Points: 
  • Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the promotion of Dr. Tommy DiRaimondo to Chief Scientific Officer.
  • Before Janux, Tommy was the co-founder of Sitari Pharmaceuticals based upon his graduate work at Stanford University with Professor Chaitan Khosla.
  • Tommy was a key leader in the Sitari drug discovery and development program, whose successful culmination was the acquisition by GlaxoSmithKline.
  • In addition to named programs, Janux is generating a number of unnamed TRACTr and TRACIr programs for potential future development.

HighField Biopharmaceuticals HF1K16 Phase 1a Data Suggests the New Immuno-Oncology Drug is Safe, Well-Tolerated and Efficacious in Solid Tumors

Retrieved on: 
Monday, January 8, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Liver, Survival, Tumor microenvironment, B cell, Stomach, Glioma, DLT, Lung, Cancer, ATRA, Myelocyte, Patient, Pharmaceutical industry

HighField Biopharmaceuticals, a clinical stage immuno-oncology company using lipid-based therapeutics to treat cancer, announced today it has completed its Phase 1a study of HF1K16.

Key Points: 
  • HighField Biopharmaceuticals, a clinical stage immuno-oncology company using lipid-based therapeutics to treat cancer, announced today it has completed its Phase 1a study of HF1K16.
  • HF1K16 is a drug encapsulated immune modulating liposome containing all-trans retinoic acid.
  • “We were especially encouraged by the outcome being correlated to the treatment duration, with the drug being tolerated for extended periods,” said Dr. Yuhong Xu, CEO of HighField.
  • For more information on the Phase 1a open label trial see NCT05388487 at clinicaltrials.gov.

Diakonos Oncology Completes Phase 1 Glioblastoma Trial Recruitment; Receives FDA Orphan Drug Designation

Retrieved on: 
Tuesday, January 2, 2024
Research, FDA, Clinical Trials, Stem Cells, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Marketing, Food, Neoplasm, B cell, Glioma, Vaccine, Person, Incidence, Doctor of Philosophy, Recurrence, Orphan drug, Pancreatic cancer, Glioblastoma, GBM, Patient, Angiosarcoma, Safety, Pharmaceutical industry

Diakonos Oncology Corporation (“Diakonos”), a clinical stage immuno-oncology company, announced today it has completed enrollment for its Phase 1 trial of DOC1021, a unique dendritic cell vaccine, for Glioblastoma Multiforme (GBM).

Key Points: 
  • Diakonos Oncology Corporation (“Diakonos”), a clinical stage immuno-oncology company, announced today it has completed enrollment for its Phase 1 trial of DOC1021, a unique dendritic cell vaccine, for Glioblastoma Multiforme (GBM).
  • With the first patient enrolled in October 2021, DOC1021 has been administered to 16 patients across four dose levels.
  • To date, DOC1021 appears to be very safe and well tolerated as there have been no attributable serious adverse events observed from DOC1021.
  • In addition to the Phase 1 trial of DOC1021 for GBM ( NCT04552886 ), the company has two other vaccines in clinical development for pancreatic cancer ( NCT04157127 ) and angiosarcoma ( NCT05799612 ).

Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions

Retrieved on: 
Monday, December 18, 2023
Patient, Immunotherapy, NGS, Neoplasm, PR, CDKN2B, CDK2, Histology, Glioma, DLT, CYCC, Lung, CDK9, PLK1, Metformin, Half-life, Melanoma, Hyperglycemia, Blood, Cyclacel, Cancer, Endometrial cancer, T-cell lymphoma, Mesothelioma, Head, Laboratory, Pancreatic cancer, MTAP, Biomarker, Tablet, Lymphoma, NSCLC, Deletion, PRMT5, Neck

BERKELEY HEIGHTS, N.J., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today interim results from its Phase 1, dose escalation 065-101 study of fadraciclib (“fadra”) in patients with advanced solid tumors and lymphoma.

Key Points: 
  • “The data suggest tumor sensitivity in patients with one or more of three abnormalities, CDKN2A, CDKN2B and/or MTAP deletion subject to confirmation in further studies.
  • The Phase 2 part of 065-101 is designed to evaluate fadra safety and efficacy in cohorts defined by histology and/or next generation sequencing (NGS).
  • “After retrospectively analyzing a subset of previously treated Phase 1 patients who experienced clinical benefit with fadra, we found four patients with CDKN2A, CDKN2B and/or MTAP deletions.
  • CDKN2B deletions occur in over 30% of several solid tumors, including bladder, glioma, pancreatic, esophageal, lung (incl.

Oncotelic Reports Q3 2023 Compared to Q3 2022 Financial Results

Retrieved on: 
Wednesday, November 15, 2023
Parkinson's disease, Pancreatic cancer, Glioma, Mesothelioma, OTCQB, Security (finance), Therapy, CFO, Disease, Patient, Artificial intelligence, PDAC, G&A, COVID-19, JV, Growth, DIPG, WalletHub, Pharmaceutical industry, Hong Kong

AGOURA HILLS, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a developer of treatments for rare and orphan indications, including Parkinson's Disease, PDAC, DIPG, and COVID-19, today announced financial results for the three months ended September 30, 2023 (“Q3 2023”) as compared to the three months ended September 30, 2022 (“Q3 2022”).

Key Points: 
  • AGOURA HILLS, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a developer of treatments for rare and orphan indications, including Parkinson's Disease, PDAC, DIPG, and COVID-19, today announced financial results for the three months ended September 30, 2023 (“Q3 2023”) as compared to the three months ended September 30, 2022 (“Q3 2022”).
  • The financial results are based on the Quarterly Report on Form 10-Q as filed with the Securities and Exchange Commission on November 14, 2023.
  • Highlights for Q3 2023 and thereafter:
    We have been enjoying the effects of the benefits of the JV transaction, between Dragon Overseas Limited (“Dragon”) and us, through the formation of GMP Biotechnology Limited (“GMP Bio” or “JV”) being reflected in our financial results.
  • “Commencing April 2022, with the culmination of the JV with Dragon, and continuing into 2023 till date, have been a good eighteen months for us.